[Expert Solution]: Compared with short-acting beta 2…

Compared with short-acting beta 2 agonists, long-acting beta 2 agonists: Should be added to therapy only when ICS use does not provide adequate asthma control. Have a rapid onset of action across the drug class. Have a significantly different pharmacodynamic profile. Are recommended as a first-line therapy in mild persistent asthma.